Literature DB >> 33837984

Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine.

Evangelos Terpos1, Ioannis P Trougakos2, Filia Apostolakou3, Ioanna Charitaki1, Aimilia D Sklirou2, Nefeli Mavrianou1, Eleni-Dimitra Papanagnou2, Christine-Ivy Liacos1, Sentiljana Gumeni2, Gianna Rentziou1, Eleni Korompoki1, Ioannis Papassotiriou3, Meletios A Dimopoulos1.   

Abstract

Entities:  

Year:  2021        PMID： 33837984     DOI： 10.1002/ajh.26185

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  63 in total

1.  Predictive Model for Adverse Events and Immune Response Based on the Production of Antibodies After the Second-Dose of the BNT162b2 mRNA Vaccine.

Authors:  Shinichi Okada; Katsuyuki Tomita; Genki Inui; Tomoyuki Ikeuchi; Hirokazu Touge; Junichi Hasegawa; Akira Yamasaki
Journal:  Yonago Acta Med       Date:  2022-02-22       Impact factor: 1.641

2.  Association of clinical and epidemiological characteristics with COVID-19 BNT162b2 mRNA vaccine short-term adverse reactions in healthcare workers.

Authors:  Filippos Filippatos; Elizabeth-Barbara Tatsi; Charilaos Dellis; Nick Dessypris; Vassiliki Syriopoulou; Athanasios Michos
Journal:  Hum Vaccin Immunother       Date:  2021-11-30       Impact factor: 3.452

3.  Covid-19 vaccination in patients with multiple myeloma: Focus on immune response.

Authors:  Heinz Ludwig; Jesús San-Miguel; Nikhil Munshi; Pieter Sonneveld; María-Victoria Mateos; Philippe Moreau; Evangelos Terpos
Journal:  Am J Hematol       Date:  2021-06-21       Impact factor: 13.265

4.  Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination.

Authors:  Gian Luca Salvagno; Brandon M Henry; Giovanni di Piazza; Laura Pighi; Simone De Nitto; Damiano Bragantini; Gian Luca Gianfilippi; Giuseppe Lippi
Journal:  Diagnostics (Basel)       Date:  2021-05-04

Review 5.  The role of sexual dimorphism in susceptibility to SARS-CoV-2 infection, disease severity, and mortality: facts, controversies and future perspectives.

Authors:  Stavroula Pegiou; Elpiniki Rentzeperi; Theocharis Koufakis; Symeon Metallidis; Kalliopi Kotsa
Journal:  Microbes Infect       Date:  2021-06-12       Impact factor: 2.700

6.  Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2.

Authors:  Jean-Louis Bayart; Laure Morimont; Mélanie Closset; Grégoire Wieërs; Tatiana Roy; Vincent Gerin; Marc Elsen; Christine Eucher; Sandrine Van Eeckhoudt; Nathalie Ausselet; Clara David; François Mullier; Jean-Michel Dogné; Julien Favresse; Jonathan Douxfils
Journal:  Microorganisms       Date:  2021-06-21

7.  Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis.

Authors:  Efstathios Kastritis; Evangelos Terpos; Aimilia Sklirou; Foteini Theodorakakou; Despina Fotiou; Eleni-Dimitra Papanagnou; Tina Bagratuni; Nikolaos Kanellias; Maria Gavriatopoulou; Ioannis P Trougakos; Meletios A Dimopoulos
Journal:  Hemasphere       Date:  2021-07-15

8.  Clinical Application of a New SARS-CoV-2 Antigen Detection Kit (Colloidal Gold) in the Detection of COVID-19.

Authors:  Evangelos Terpos; Ioannis Ntanasis-Stathopoulos; Miha Skvarč
Journal:  Diagnostics (Basel)       Date:  2021-05-30

9.  Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine.

Authors:  Maria Gavriatopoulou; Evangelos Terpos; Efstathios Kastritis; Alexandros Briasoulis; Sentiljana Gumeni; Ioannis Ntanasis-Stathopoulos; Aimilia D Sklirou; Panagiotis Malandrakis; Evangelos Eleutherakis-Papaiakovou; Magdalini Migkou; Ioannis P Trougakos; Meletios A Dimopoulos
Journal:  Clin Exp Med       Date:  2021-07-20       Impact factor: 5.057

10.  Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients.

Authors:  Cristina Bergamaschi; Evangelos Terpos; Margherita Rosati; Matthew Angel; Jenifer Bear; Dimitris Stellas; Sevasti Karaliota; Filia Apostolakou; Tina Bagratuni; Dimitris Patseas; Sentiljana Gumeni; Ioannis P Trougakos; Meletios A Dimopoulos; Barbara K Felber; George N Pavlakis
Journal:  Cell Rep       Date:  2021-07-23       Impact factor: 9.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.